# China Orient Asset Management (International) Holding

> China Orient Asset Management (International) Holding is a VC fund backing Health Care. See 6 investments, check sizes, portfolio and contact details…

- Type: VC Fund
- Location: Central, Hong Kong
- Total investments: 6
- Last investment: Oct 2025
- Lead investor: 17%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/china-orient-asset-c-corporation/
- Website: https://www.coamci.com

China Orient Asset Management (International) Holding is a VC fund in Central focused on Health Care and Pharmaceutical. Headquartered in Hong Kong, China Orient Asset Management (International) Holding Limited (COAMCI), a wholly-owned subsidiary of China Orient Asset Management Co., Ltd. (COAMC), which founded in 2002 and subsequently restructured and renamed in June 2011.COAMCI is one of the Group’s primary overseas platform focusing on investment, assetmanagement etc, as a bridge between domestic resources and overseas markets, delivering a specialized, diversified and comprehensive range of financial services solution. Fully utilizing the company’s multi-market and multi-currency capabilities to its advantage. With the deep understanding of the Chinese market and the benefit of investment acumen in global markets, COAMCI has kept steady growth in asset value.

## Contacts

5 contacts available for China Orient Asset Management (International) Holding. Shizune tracks 3 team members at China Orient Asset Management (International) Holding. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/china-orient-asset-management-international-holding?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 33% |
| Pharmaceutical | 2 | 33% |
| Travel | 1 | 17% |
| Aerospace | 1 | 17% |
| Biopharma | 1 | 17% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 33% |
| Series D | 1 | 17% |
| Funding Round | 1 | 17% |
| Private Equity | 1 | 17% |
| Post-IPO Equity | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 5 | 83% |
| Canada | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Chloe Zhang | COAMCI Department Head | 0 | https://shizune.co/investors/profile/chloe-zhang-1 |
| Quan Wang | CEO | 0 | https://shizune.co/investors/profile/quan-wang |
| Ziqiang Wang | CFO | 0 | https://shizune.co/investors/profile/ziqiang-wang |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tianbing Technology | Tianbing Technology is an advanced aerospace propulsion system supplier and aerospace vehicle provider. Tianbing Technology independently develops the next-generation ambient temperature green HCP liquid propellant and minimalist aerospace propulsion system. As an upgraded product of traditional chemical propulsion system, it can meetcost-effective aerospace. Advance system supporting needs. The next-generation green HCP aerospace propulsion system, first tested by Tianbing Technology, can be used in the small-vehicle main power and launch vehicle upper-level propulsion system. | $350.7M | Series D | Oct 09, 2025 |  |
| Shanghai Wai Gaoqiao Free Trade Zone Development | Shanghai Wai Gaoqiao Free Trade Zone Development is a publicly traded firm that offers the community a multipurpose free trade zone. They support the development and construction of urban living areas, the promotion and stabilization of investments, the cultivation of industries, and operation services. Additionally, they engage in industrialproduction, logistical services, and the leasing and distribution of real estate. | $339.2M | Post-IPO Equity | Apr 17, 2025 |  |
| ChangXin Memory Technologies | ChangXin Memory Technologies specializes in manufacturing dynamic random-access memory (DRAM) semiconductor products. | $1.2B | Series C | Feb 17, 2022 |  |
| Suzhou Kintor Pharmaceuticals | Kintor founded in Suzhou in 2009, focusing on prostate cancer, breast cancer and liver cancer which account for more than 50% of the global cancer population and lack of effective treatment method. They have a product pipeline built on proprietary R&D and licensing arrangement, aiming to provide the best treatment plans for huge unmet patientneeds. They focus on developing a full R&D and commercialization platform for “best-in-class” and “first-in-class” novel drugs. | $44M | Series C | Jan 12, 2018 |  |
| Yixin Capital | The firm aims to develop a consumer-centric automotive transaction platform which connects consumers with a partner network that includes automakers, auto dealers, financing and insurance partners, as well as aftermarket service providers. | $567M | Private Equity | May 12, 2017 |  |
| Angiotech Pharmaceuticals | Angiotech is a Vancouver, British Columbia pharmaceutical company. Its products enhance the performance of medical devices and biomaterials through the use of pharmacotherapeutics. Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarilyfor local diseases or for complications associated with medical device implants, surgical interventions and acute injury. |  |  | Mar 21, 2017 |  |

6 of 6 investments shown.

## Co-investors
- [Tencent](https://shizune.co/investors/profile/tencent) — VC Fund, 2 deals together
- [ABCI Investment Management](https://shizune.co/investors/profile/abci-investment-management) — VC Fund, 1 deal together
- [Alibaba Group](https://shizune.co/investors/profile/alibaba) — VC Fund, 1 deal together
- [Bank of China Financial Assets Investment](https://shizune.co/investors/profile/bank-of-china-financial-assets-investment) — VC Fund, 1 deal together
- [Beijing Jiaotong United](https://shizune.co/investors/profile/beijing-jiaotong-united) — VC Fund, 1 deal together
- [Bitauto Holdings](https://shizune.co/investors/profile/bitauto-holdings) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does China Orient Asset Management (International) Holding invest in?

China Orient Asset Management (International) Holding invests primarily in Health Care, Pharmaceutical and Travel startups, most often at Series C and Series D stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact China Orient Asset Management (International) Holding?

Public channels for China Orient Asset Management (International) Holding include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at China Orient Asset Management (International) Holding?

The team at China Orient Asset Management (International) Holding includes Chloe Zhang (COAMCI Department Head), Quan Wang (CEO) and Ziqiang Wang (CFO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co